ClinicalTrials.gg
RecruitingNCT05988645Updated Oct 8, 2026

Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II)

An interventional study of MiWEndo System in Colorectal Cancer, Colorectal Polyp and Colorectal Adenoma, sponsored by MiWEndo Solutions S.L.. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by MiWEndo Solutions S.L. · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.
Updated Oct 8, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 463 studies in Colorectal Neoplasms with a site in Spain — 97 open to participants now, 150 under way, 18 of them phase 3. Colorectal Neoplasms · Spain.

Planned enrollment
329th of 405
50 · median 167
Started
2023
with 29 others
No phase
61 of 463
11 open now
Primary completion
2026-11
later than 43 of 149 live
Registered
364th of 463
by date

Among the 463 studies in Colorectal Neoplasms with a site in Spain, this one is the 329th largest by planned enrollment of the 405 interventional ones that give a count, is one of 30 that started in 2023, is one of 61 with no phase, reaches primary completion later than 43 of the 149 other live ones, and was the 364th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

97 of the 463 studies in Colorectal Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

92 more — sign in →

All 97 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Colorectal Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

The study involves the planned use of a new microwave-based device during colonoscopy procedures in 50 patients to assess the performance and safety of its use for detection of colorectal polyps and lack of normal clinical practice modification. The device is a final design version, which has been previously tested in several preclinical studies (including phantom studies, an ex vivo study with human tissues, and an in vivo study with porcine model) and in a pilot study in humans (NCT05477836)

Read the detailed description

This study is designed as a single-center prospective, non-comparative study in 50 patients, whereby data will be subject to an analytical description, rather than to a statistical treatment (refer to Statistical design and analysis).

In this study the principal aims are to assess the performance and safety of the device for the detection of colorectal polyps when used as an accessory to colonoscopy. Relevant claims to verify in this study are that the device will detect in first instance polyps not detected initially with the endoscopic image and can be used without ADEs, without any change in the current clinical practice, as well as without any major difficulty by the endoscopist, neither in the preparation nor in the use of the device during exploration.

In addition, in the first phase of the study (n=15 patients), the study aims to gather real clinical data with the use of the device to optimise the processing software that will be key to demonstrate MiWEndo\'s performance on the second part of the study (n=35 patients).

Consequently, principal and secondary objectives of this investigation, are:

Principal objectives:

  • To assess the performance of MiWEndo-assisted colonoscopy in the detection of colorectal polyps.
  • To assess the safety of MiWEndo-assisted colonoscopy.

Secondary objectives:

  • To assess the perception of difficulty by the endoscopist when the device is used.
  • To provide exploratory analysis of differences in MiWEndo-assisted colonoscopy in different groups of patients to guide future RCT.
  • To assess the patient's comfort.
03

Conditions studied

  • Colorectal Cancer
  • Colorectal Polyp
  • Colorectal Adenoma
  • Colorectal Adenomatous Polyp
  • Colorectal Adenocarcinoma
  • Colorectal Neoplasms

Keywords

  • microwave imaging
  • colonoscopy
  • early diagnosis
  • colorectal cancer screening
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Patients older than 18-year-old referred for a screening or surveillance colonoscopy because of a high-risk condition of developing colorectal cancer or having colorectal polyps as fecal occult blood test (FOBT) positive, previously resected polyps under surveillance, hereditary polyposis syndromes, Lynch Syndrome or familial cancer.

These criteria will ensure the probability of finding polyps during the explorations.

All the patients will give written .

Exclusion criteria

Exclusion Criteria:

  • Patients at a high risk of having major complications as perforation or hemorrhage, suspected or proven lower gastrointestinal bleeding, non-correctable coagulopathy or anticoagulant/clopidogrel therapy during procedure, inadequate bowel cleansing.
  • ASA-IV patients.
  • Urgent colonoscopy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    MiWEndo + colonoscope

    All patients will be explored with MiWEndo as an accessory to colonoscopy

    Device: MiWEndo System

Interventions

  • DeviceMiWEndo System

    All colonoscopies will be performed with high-definition technology. The MiWEndo System will be fitted to the tip of the endoscope before colonoscopy is started and connected to the microwave processor unit. Endoscopies will be performed by experienced endoscopists who will be previously trained on the use of the MiWEndo System. The MiWEndo Analyzer will be managed by the assistant. At the beginning of the extubation, the MiWEndo System will be turned on and the endoscopist will put music headphones on (blind to the results of MiWEndo). In case one of them identifies a polyp, the exploration will be stopped and check if it has been detected by the alternative method as well. All the polyps will be resected and sent to the Pathological Department for histological analysis following the usual clinical practice. A stopwatch will be used to measure both total procedure time and withdrawal time.

06

What researchers measure

Primary outcomes

  1. Number of polyps

    With MiWEndo assisted colonoscopy, detect at least one polyp before colonoscopy in 10% of patients.

    Time frame: During the procedure.

  2. Number of adverse events.

    Number of adverse events related with the use of the MiWEndo using the lexicon proposed by the American Society of Gastrointestinal Endoscopy (ASGE) (Cotton PB et al. GIE 2010;71:446-54).

    Time frame: During the procedure and up to 2 weeks after.

  3. Number of mural injuries.

    Mural injuries related with the use of the MiWEndo.

    Time frame: During the procedure and up to 2 weeks after.

Secondary outcomes

  1. Number and size (adenomas and polyps).

    The number and size of all lesions (adenomas and all polyps) detected with MiWEndo-assisted colonoscopy.

    Time frame: During procedure.

  2. True positives (TP), False positives (FP), False negatives (FN).

    The concordance with the lesions detected by the standard colonoscopy (TP, FP, FN).

    Time frame: During procedure.

  3. Patients' comfort.

    Patients' feedback related to colonoscopy using the Gloucester comfort score that ranges from 1 (no discomfort) to 5 (severe discomfort).

    Time frame: Immediately after the procedure and 2 weeks after.

  4. Perception of difficulty.

    Perception of difficulty by the endoscopist based on a 5-points Likert scale (very easy to very difficult or very much to very little).

    Time frame: Immediately after the procedure.

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Nov 2026, 39 months after the start.

Of 58 industry-sponsored interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 37. This study's planned 39 months is above that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Dec 2025 → Nov 2026 and completion Dec 2025 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2023
First posted
Aug 14, 2023
StartActual
Aug 1, 2023
Primary completionEst.
Nov 29, 2026was Dec 2025
CompletionEst.
Nov 29, 2026was Dec 2025
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 29, 2025→Nov 29, 2026
Oct 8, 2026
Study completion
Dec 29, 2025→Nov 29, 2026
Oct 8, 2026
Eligibility
1 inclusion criterion added, 1 removed
What changed in the criteria
Inclusion criteria
  • Removed- Patients with a previously detected polyp in the rectum referred for resection.
  • Added- Patients older than 18-year-old referred for a screening or surveillance colonoscopy because of a high-risk condition of developing colorectal cancer or having colorectal polyps as fecal occult blood test (FOBT) positive, previously resected polyps under surveillance, hereditary polyposis syndromes, Lynch Syndrome or familial cancer.
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Primary completion Dec 29, 2025→Nov 29, 2026
    Study completion Dec 29, 2025→Nov 29, 2026
    Eligibility 1 inclusion criterion added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • Removed- Patients with a previously detected polyp in the rectum referred for resection.
    • Added- Patients older than 18-year-old referred for a screening or surveillance colonoscopy because of a high-risk condition of developing colorectal cancer or having colorectal polyps as fecal occult blood test (FOBT) positive, previously resected polyps under surveillance, hereditary polyposis syndromes, Lynch Syndrome or familial cancer.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05988645
Lead sponsor
MiWEndo Solutions S.L.
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Aug 1, 2023
Primary completion
Nov 29, 2026 (estimated)
Completion
Nov 29, 2026 (estimated)
Last update
Oct 8, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion